Your browser doesn't support javascript.
A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates.
An, Yaling; Li, Shihua; Jin, Xiyue; Han, Jian-Bao; Xu, Kun; Xu, Senyu; Han, Yuxuan; Liu, Chuanyu; Zheng, Tianyi; Liu, Mei; Yang, Mi; Song, Tian-Zhang; Huang, Baoying; Zhao, Li; Wang, Wen; A, Ruhan; Cheng, Yingjie; Wu, Changwei; Huang, Enqi; Yang, Shilong; Wong, Gary; Bi, Yuhai; Ke, Changwen; Tan, Wenjie; Yan, Jinghua; Zheng, Yong-Tang; Dai, Lianpan; Gao, George F.
  • An Y; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, 101408, People's Republic of China.
  • Li S; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.
  • Jin X; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.
  • Han JB; School of Life Sciences, University of Science and Technology of China, Hefei, Anhui, 230026, People's Republic of China.
  • Xu K; Kunming National High-Level Biosafety Research Center for Non-human Primates, Center for Biosafety Mega-Science, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650107, People's Republic of China.
  • Xu S; Key Laboratory of Tropical Translational Medicine of Ministry of Education, School of Tropical Medicine and Laboratory Medicine, The First Affiliated Hospital, Hainan Medical University, Hainan, 571199, People's Republic of China.
  • Han Y; Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.
  • Liu C; Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.
  • Zheng T; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, 101408, People's Republic of China.
  • Liu M; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.
  • Yang M; Laboratory of Animal Infectious Diseases, College of Animal Sciences and Veterinary Medicine, Guangxi University, Nanning, 530000, People's Republic of China.
  • Song TZ; Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.
  • Huang B; Zhejiang University School of Medicine, Hangzhou 310058, People's Republic of China.
  • Zhao L; CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.
  • Wang W; CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.
  • A R; Key Laboratory of Animal Models and Human Disease Mechanism of the Chinese Academy of Sciences, Kunming Institute of Zoology, Chinese Academic of Sciences, Kunming, 650223, People's Republic of China.
  • Cheng Y; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
  • Wu C; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
  • Huang E; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
  • Yang S; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
  • Wong G; Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Anhui, 230088, People's Republic of China.
  • Bi Y; Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Anhui, 230088, People's Republic of China.
  • Ke C; Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Anhui, 230088, People's Republic of China.
  • Tan W; Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Anhui, 230088, People's Republic of China.
  • Yan J; CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, People's Republic of China.
  • Zheng YT; Department of Microbiology-Infectiology and Immunology, Laval University, Quebec City G1, Canada.
  • Dai L; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.
  • Gao GF; CAS Center for Influenza Research and Early-Warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing, People's Republic of China.
Emerg Microbes Infect ; 11(1): 1058-1071, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-1752040
ABSTRACT
Safe, efficacious, and deployable vaccines are urgently needed to control COVID-19 in the large-scale vaccination campaigns. We report here the preclinical studies of an approved protein subunit vaccine against COVID-19, ZF2001, which contains tandem-repeat dimeric receptor-binding domain (RBD) protein with alum-based adjuvant. We assessed vaccine immunogenicity and efficacy in both mice and non-human primates (NHPs). ZF2001 induced high levels of RBD-binding and SARS-CoV-2 neutralizing antibody in both mice and non-human primates, and elicited balanced TH1/TH2 cellular responses in NHPs. Two doses of ZF2001 protected Ad-hACE2-transduced mice against SARS-CoV-2 infection, as detected by reduced viral RNA and relieved lung injuries. In NHPs, vaccination of either 25 µg or 50 µg ZF2001 prevented infection with SARS-CoV-2 in lung, trachea, and bronchi, with milder lung lesions. No evidence of disease enhancement was observed in both animal models. ZF2001 has been approved for emergency use in China, Uzbekistan, Indonesia, and Columbia. The high safety, immunogenicity, and protection efficacy in both mice and NHPs found in this preclinical study was consistent with the results in human clinical trials.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Topics: Vaccines Limits: Animals / Humans Language: English Journal: Emerg Microbes Infect Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Topics: Vaccines Limits: Animals / Humans Language: English Journal: Emerg Microbes Infect Year: 2022 Document Type: Article